AlphaYou
Overview
Smart money at a glance
Filings to Oct 1, 2026No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- $0No open-market trades
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 3 added, 0 cutMore adding
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Key stats
Fundamentals Sep 30- Open
- $34.94
- 52-wk high
- $35.70
- High
- $35.64
- 52-wk low
- $23.62
- Low
- $34.89
- Prev close
- $35.36
- Mkt cap
- $22.20B
- P/E
- 28.2x
- Volume
- 3.83M
- Fwd P/E
- 15.1x
- Beta
- 0.70
- P/S
- 5.4x
- P/B
- 3.6x
- Profit margin
- +19.1%
- Op margin
- +35.2%
- ROE
- +14.0%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about GMAB filings
Are insiders buying or selling Genmab AS (GMAB) stock?
Neither. Genmab AS (GMAB) insiders filed no open-market purchases or sales in the 90 days to Oct 1, 2026, according to SEC Form 4 filings.
Which members of Congress have traded GMAB recently?
None. No member of Congress disclosed a GMAB trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this GMAB smart-money data?
This summary uses filings available on Oct 1, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position.
What funds are doing
Buys/Adds (3)
- CI
Citadel
$68.0M
bought
- QR
Qube Research
$28.2M
added
- JC
JPMorgan Chase
$13.6M
added
How top traders are positioned
No tracked top-trader positions in GMAB right now.
Live Hyperliquid positioning - not every stock is covered
Activist stakes, short interest & more
Earnings
Earnings came in 45.9% above what analysts expected.
Earnings per share
$0.37 expected
Reports Nov 5, 2026, in 35 days
Estimates as of Oct 1, 2026
EPS expected
$0.24 to $0.41
Revenue expected
11 analysts
Last 30 days
Split both ways
Estimate drift
Change in 30 days
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $1.02B | $1.05B | $899.3M | $1.16B |
| Cost of what it sold | $58.0M | $80.8M | $65.2M | $84.0M |
| Gross profit | $964.0M | $974.1M | $834.1M | $1.07B |
| What it spent | ||||
| Research and development | $357.0M | $524.4M | $441.6M | $459.0M |
| Sales and admin | $148.0M | $208.0M | $166.0M | $205.0M |
| Total operating expenses | $505.0M | $731.8M | $608.2M | $664.0M |
| What was left | ||||
| Operating profit | $459.0M | $242.3M | $225.8M | $407.0M |
| Interest on debt | $3.0M | $43.9M | $112.4M | $110.0M |
| Profit before tax | $482.0M | $54.8M | $74.3M | $295.0M |
| Tax | $81.0M | $23.9M | $21.1M | -$8.0M |
| Net profit | $401.0M | $30.9M | $53.2M | $303.0M |
| EBITDA | $503.0M | $98.7M | $186.7M | $431.0M |
Technicals
Price structure
This stock is in a strong uptrend, and looks overbought after a fast run-up.
Trend
Strong uptrend
85 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Genmab stock at DKK 2,277 on September 25, 2026, up 0.40 percent
Leans bullishSep 26Genmab Grants New Employee Restricted Stock Units and Warrants
NeutralSep 26Genmab (CPSE:GMAB) Stock Looks Fairly Valued Following Its 25% Gain
NeutralSep 25Genmab stock gains 0.8 percent ahead of the open
BullishSep 24Employees at Genmab (GMAB) receive free share awards and rights to buy shares at DKK 2,268.
NeutralSep 24Grant of Restricted Stock Units and Warrants to Employees in Genmab
BullishSep 24Genmab A/S (GMAB) 10K Form and Latest SEC Filings 2026
NeutralSep 24Genmab AS stock hits 52-week high at 35.48 USD
BullishSep 23